ABL
Prabha Chandrasekaran is currently serving as the Head of Scientific Design and Execution at ABL since October 2021. Prior to this, they held positions at Walter Reed Army Institute of Research, The National Institutes of Health, University of Maryland, National Institute of Allergy and Infectious Diseases, and National Institute For Research In Tuberculosis. Their experience includes roles such as Associate Lab Director, Senior Scientist, Research Assistant Professor, and Postdoctoral Fellow. Additionally, they have been involved in research projects at the Indian Council of Medical Research and Institut für Medizinische Mikrobiologie und Hygiene as a Ph.D fellow.
This person is not in any offices
ABL
From development to market ABL Europe provides GMP viral vectors, contributing to the success of our clients’ immunotherapy innovations. ABL Europe SAS is a pure-play GMP CMO licensed in accordance with EMA, completely dedicated to the provision of viral vector GMP contract manufacturing services, and a subsidiary of ABL Inc. under the corporate ownership of Institut Mérieux. ABL has a strong technical & regulatory track record in process development, scale-up & GMP manufacturing of filterable & non-sterile filterable (aseptic processing) viral vectors used in all phases of clinical development globally. With different adherent platforms (< 60 m2) and suspension (< 500 L) capabilities for drug substance and drug product (< 10,000 vials per batch) in-house, experience in process characterisation and validation, ABL provides its clients with a long-term strategic manufacturing option through clinical development & licensure for a range of virus vector gene therapy & vaccine products. ABL Europe’s clients are located worldwide.